Core Viewpoint - The Chinese traditional medicine sector is experiencing active market performance, driven by a new government initiative aimed at high-quality development in the industry by 2030 [1] Group 1: Market Performance - As of the report, several companies in the traditional Chinese medicine sector have seen significant stock price increases: China Traditional Chinese Medicine (00570) up 5.8% to HKD 2.19, Yuantang (00897) up 4.35% to HKD 0.36, Tongrentang Guoyao (03613) up 2.38% to HKD 9.03, and Tongrentang Technology (01666) up 1.83% to HKD 4.44 [1] Group 2: Government Initiative - On February 5, the Ministry of Industry and Information Technology and seven other departments issued the "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" [1] - The plan aims to cultivate leading enterprises in the traditional Chinese medicine industry and establish 60 high-standard production bases for Chinese medicinal materials by 2030 [1] - It also emphasizes the approval and market launch of innovative traditional Chinese medicines and the development of ten new major traditional Chinese medicine products [1] Group 3: Industry Outlook - According to Everbright Securities, the investment logic in the traditional Chinese medicine sector will shift from "cost recovery" to "value growth" by 2026, driven by continuous policy benefits and improved operational efficiency of companies [1] - The acceleration of internationalization for traditional Chinese medicine products is expected to create new growth opportunities for companies with product advantages and international capabilities in the global market [1]
港股异动 | 中医药概念逆市活跃 中国中药(00570)一度涨超7% 中药产业迎来政策利好